Elevated cell surface levels of the human epidermal growth factor receptor subunit 3 (HER3) is associated with resistance to a number of signal-blocking breast cancer treatments, including inhibitors of EGF-R (lapatinib), HER2 (lapatinib, trastuzumab, T-DM1), HER2-3 (pertuzumab), and combination therapy. Additionally, HER3 elevation has been identified on untarget-able tumors such as triple-negative breast cancer (TNBC), including TNBC with acquired resistance to EGF-R inhibition. Patients with such refractory tumors currently have limited treatment options and a poor prognosis. Moreover, as up to 70% of cases resist or acquire resistance to signal-blocking therapies, an alternative approach addressing this important clinical problem has the potential for significant clinical impact. We have developed a self-assembling nanobiological particle, HerDox, which uses HER3 as a portal for targeted entry of toxic molecules. In contrast to receptor-targeted antibodies and tyrosine kinase inhibitors currently used in the clinic, HerDox circumvents the need to modulate signaling and can induce rapid entry of toxic molecules into tumor cells by receptor-mediated endocytosis and membrane penetration. We have previously shown that HerDox can elicit targeted toxicity to HER2+ tumors due to the prevalence of HER2-3 heterodimers on the tumor cell surface, while sparing heart and liver tissue. We are currently exploring the capacity for HerDox to target toxicity to tumors that resist HER2 inhibitors. Our preliminary studies show that HerDox exhibits improved therapeutic efficacy on tumor cell lines with acquired resistance to HER2 inhibitors over parental tumor cells, due in part to the elevated HER3 expression associated with the HER2+ drug resistance. Here we will evaluate the mechanism and efficacy of HerDox in several in vitro and in vivo models representing distinct scenarios along the spectrum of resistance. We will probe the additional factors contributing to the high efficacy of HerDox on tumors with acquired resistance, as these cells exhibit moderately elevated levels of HER3. We will evaluate the efficacy of using signal-inhibitors as adjuvants for HerDox treatment on both nave and inherently-resistant tumors, given the preliminary finding that pretreatment of parental breast cancer cell lines in vitro with trastuzuma induced elevation of HER3. We will also evaluate the efficacy of HerDox on TNBC in an immunocompetent model of disseminated breast cancer and assess whether EGF-R inhibition further sensitizes these tumors to HerDox via HER3 elevation. In all aims of this study, HerDox will be evaluated in comparison to trastuzumab, lapatinib, pertuzumab, T-DM1, and combination treatments. The advantages over signal-blocking inhibitors seen in our preliminary studies suggest that HerDox is likely to present an effective approach in addressing tumors that resist current targeted treatments used in the clinic.

Public Health Relevance

The majority of tumor-targeted therapies currently used in the clinic are aimed at blocking signal transduction that normally supports cell growth and survival, but the majority of cases do not respond to signal-blocking therapies, while the majority of those who do initially respond develop resistance within one year. As these resistant tumors acquire mechanisms that sustain signaling in the face of targeted treatment, there is a need for alternative strategies that are not reliant on signal-modulation. This study addresses that need by introducing a nanobiologic with the capacity to not only specifically home to such resistant tumors, but also deliver toxic molecules through tumor-targeted penetration while circumventing the need to modulate signaling.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA129822-07
Application #
9324876
Study Section
Nanotechnology Study Section (NANO)
Program Officer
Fu, Yali
Project Start
2009-05-01
Project End
2020-07-31
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
7
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Sims, Jessica D; Taguiam, Jan Michael; Alonso-Valenteen, Felix et al. (2018) Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. J Control Release 271:127-138
Ha, Sung Gil; Dileepan, Mythili; Ge, Xiao Na et al. (2018) Knob protein enhances epithelial barrier integrity and attenuates airway inflammation. J Allergy Clin Immunol 142:1808-1817.e3
Qu, Ying; Han, Bingchen; Gao, Bowen et al. (2017) Differentiation of Human Induced Pluripotent Stem Cells to Mammary-like Organoids. Stem Cell Reports 8:205-215
Qu, Ying; Zhou, Bo; Yang, Wei et al. (2016) Transcriptome and proteome characterization of surface ectoderm cells differentiated from human iPSCs. Sci Rep 6:32007
Chung, Alice; Choi, Michael; Han, Bing-chen et al. (2015) Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clin Breast Cancer 15:448-457.e2
Sims, Jessica D; Hwang, Jae Youn; Wagner, Shawn et al. (2015) A corrole nanobiologic elicits tissue-activated MRI contrast enhancement and tumor-targeted toxicity. J Control Release 217:92-101
Blumenfeld, Carl M; Sadtler, Bryce F; Fernandez, G Esteban et al. (2014) Cellular uptake and cytotoxicity of a near-IR fluorescent corrole-TiO2 nanoconjugate. J Inorg Biochem 140:39-44
Medina-Kauwe, Lali K (2013) Development of adenovirus capsid proteins for targeted therapeutic delivery. Ther Deliv 4:267-77
Hwang, Jae Youn; Farkas, Daniel L; Medina-Kauwe, Lali K (2013) Analysis of targeted viral protein nanoparticles delivered to HER2+ tumors. J Vis Exp :
Hwang, Jae Youn; Lee, Jungwoo; Lee, Changyang et al. (2012) Fluorescence response of human HER2+ cancer- and MCF-12F normal cells to 200MHz ultrasound microbeam stimulation: a preliminary study of membrane permeability variation. Ultrasonics 52:803-8

Showing the most recent 10 out of 21 publications